Welcome to our dedicated page for Alto Neuroscienc SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alto Neuroscience filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing precision medicines for neuropsychiatric disorders. Form 8-K reports cover operating and financial results, clinical updates for programs such as ALTO-101 and ALTO-207, and material definitive agreements tied to private placements of common stock and pre-funded warrants.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and proposed amendments to the company’s equity incentive and employee stock purchase plans. The filings also identify ANRO common stock registered on the New York Stock Exchange and the company’s emerging growth company status.
Alto Neuroscience (ANRO) reported unaudited results for the quarter ended June 30, 2025 showing continued clinical progress alongside ongoing operating losses. Cash and cash equivalents were $147.6 million and restricted cash $0.5 million at June 30, 2025, down from $168.2 million at year-end. The company recorded a net loss of $17.7 million for the three months and $32.9 million for the six months ended June 30, 2025, with R&D expense of $23.1 million and G&A of $11.3 million for the six-month period. Accumulated deficit totaled $171.3 million. Financing activity included proceeds from a $20.0 million draw under an amended term loan and an increase in term loan principal and related debt issuance costs; term loan maturity extended to January 1, 2029 with a weighted-average interest rate of 12.96% recorded in 2025. The company has a $2.0 million Convertible Grant Agreement with Wellcome, classified at fair value. Clinical programs advanced: topline data expected mid-2026 for ALTO-300 and in H2 2026 for ALTO-100; acquisition of ALTO-207 and ALTO-208 was completed in May 2025. Management notes continued reliance on external financing to fund operations.
Alto Neuroscience reported results for the fiscal quarter ended June 30, 2025; a press release is furnished as Exhibit 99.1 to this report.
The company’s Board increased from five to six members and appointed Ramiro (Raymond) Sanchez, M.D., age 64, as an independent Class II director with a term expiring at the 2026 Annual Meeting. Dr. Sanchez brings more than 20 years of life sciences experience, including roles as Chief Medical Officer and senior global clinical development positions, and currently serves as a Senior Advisor at Bain Capital Life Sciences.
Under the Non-Employee Director Compensation Policy Dr. Sanchez will receive an initial option grant to purchase 30,574 shares vesting in equal monthly installments over three years, an annual option grant of 15,287 shares, a $40,000 annual cash retainer plus a $5,000 annual NCGC retainer, and standard indemnification. The Board also rebalanced director classes and updated committee memberships.
Alto Neuroscience (NYSE:ANRO) filed an 8-K announcing a material clinical milestone. A press release (Ex. 99.1) reports positive pharmacodynamic results and biomarker identification from an exploratory Phase 2 proof-of-concept trial of lead candidate ALTO-203.
Key points:
- Phase 2 study delivered a favorable pharmacodynamic signal; no numerical efficacy or safety data were released.
- New biomarker is positioned as a tool for future patient selection and trial design.
- No changes to strategy, guidance, or capital structure disclosed.
The update may de-risk ALTO-203 ahead of planned later-stage studies and could influence investor sentiment.